Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
TMO 
Thermo Fisher Scientific Inc (TMO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: TMO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
31 Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $651.52
1 Year Target Price $651.52
| 18 | Strong Buy |
| 7 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 18.85% | Avg. Invested days 42 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 232.51B USD | Price to earnings Ratio 35.71 | 1Y Target Price 651.52 |
Price to earnings Ratio 35.71 | 1Y Target Price 651.52 | ||
Volume (30-day avg) 31 | Beta 0.91 | 52 Weeks Range 384.82 - 628.08 | Updated Date 01/10/2026 |
52 Weeks Range 384.82 - 628.08 | Updated Date 01/10/2026 | ||
Dividends yield (FY) 0.28% | Basic EPS (TTM) 17.33 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 15.02% | Operating Margin (TTM) 19.28% |
Management Effectiveness
Return on Assets (TTM) 4.94% | Return on Equity (TTM) 13.12% |
Valuation
Trailing PE 35.71 | Forward PE 24.45 | Enterprise Value 260000937783 | Price to Sales(TTM) 5.32 |
Enterprise Value 260000937783 | Price to Sales(TTM) 5.32 | ||
Enterprise Value to Revenue 5.94 | Enterprise Value to EBITDA 23.09 | Shares Outstanding 375708059 | Shares Floating 374795088 |
Shares Outstanding 375708059 | Shares Floating 374795088 | ||
Percent Insiders 0.15 | Percent Institutions 92.9 |
Upturn AI SWOT
Thermo Fisher Scientific Inc
Company Overview
History and Background
Thermo Fisher Scientific Inc. was formed in 2006 through the merger of Thermo Electron and Fisher Scientific. Thermo Electron, founded in 1956, specialized in analytical instruments, while Fisher Scientific, founded in 1902, was a leading distributor of laboratory equipment and supplies. The merger created a powerhouse in the scientific instrumentation and laboratory services sector. Significant milestones include numerous strategic acquisitions that have expanded its product portfolio and market reach. The company has evolved into a comprehensive solutions provider for scientific research, diagnostics, and industrial applications.
Core Business Areas
- Life Sciences Solutions: Provides a broad range of instruments, reagents, consumables, and services to researchers in academic, pharmaceutical, and biotechnology settings. This includes products for genomics, proteomics, cell biology, and drug discovery.
- Analytical Instruments: Offers a wide array of analytical instruments for laboratory and industrial applications, including mass spectrometry, chromatography, elemental analysis, and molecular spectroscopy.
- Specialty Diagnostics: Delivers diagnostic solutions, including immunoassay and molecular diagnostic tests, and instruments for clinical and applied markets, such as infectious disease testing and food safety.
- Laboratory Products and Services: Includes laboratory equipment, consumables, chemicals, and services such as lab design, build, and management, serving a broad spectrum of scientific disciplines.
Leadership and Structure
Thermo Fisher Scientific is led by a seasoned executive team, with its headquarters in Waltham, Massachusetts. The company operates through a divisional structure aligned with its core business areas, enabling specialized focus and market responsiveness. Its organizational structure is designed to integrate its diverse product lines and services effectively, fostering collaboration and innovation across its global operations.
Top Products and Market Share
Key Offerings
- Market Share Data: Difficult to isolate a single market share percentage for all mass spectrometers, but Thermo Fisher is a dominant player in high-end segments.
- Product Name 1: Mass Spectrometers (e.g., Orbitrap, Q Exactive): Leading instruments for precise molecular identification and quantification. Competitors include Agilent Technologies, SCIEX, and Shimadzu. Market share is significant but specific figures vary by sub-segment.
- Market Share Data: Dominant player in certain NGS workflows, particularly in academic research.
- Product Name 2: Next-Generation Sequencing (NGS) Solutions: Comprehensive platforms and reagents for genetic analysis, crucial for research and clinical diagnostics. Competitors include Illumina, Pacific Biosciences, and Oxford Nanopore Technologies.
- Market Share Data: Strong market position in both Gas Chromatography (GC) and Liquid Chromatography (LC) segments.
- Product Name 3: Chromatography Systems (GC, LC): Essential tools for separating and analyzing chemical mixtures in various industries. Competitors include Agilent Technologies, Shimadzu, and Waters Corporation.
- Market Share Data: Holds a substantial share due to its extensive distribution network and broad product catalog.
- Product Name 4: Laboratory Consumables (e.g., pipettes, vials, reagents): A vast array of essential supplies for daily laboratory operations. Competitors are numerous, including VWR (Avantor), MilliporeSigma (Merck KGaA), and many smaller specialized suppliers.
Market Dynamics
Industry Overview
Thermo Fisher Scientific operates within the broader scientific and healthcare industries, encompassing life sciences research, diagnostics, and industrial analytical markets. These industries are characterized by continuous innovation, driven by scientific advancements, increasing healthcare demands, and the need for accurate and efficient analysis. The market is dynamic, with a growing emphasis on personalized medicine, biopharmaceutical development, and advanced manufacturing quality control.
Positioning
Thermo Fisher Scientific is a global leader in serving science, offering an unparalleled breadth of products, services, and solutions. Its competitive advantages stem from its extensive product portfolio, strong brand recognition, robust R&D capabilities, global distribution network, and a successful track record of strategic acquisitions. The company is well-positioned to capitalize on growth trends in biotechnology, pharmaceutical, and diagnostic sectors.
Total Addressable Market (TAM)
The total addressable market for Thermo Fisher Scientific is vast, encompassing segments like laboratory research, clinical diagnostics, pharmaceutical and biotech production, and industrial testing. Various estimates place the global TAM for these combined sectors in the hundreds of billions of dollars annually, with consistent growth projections. Thermo Fisher Scientific, with its broad offerings, is positioned to capture a significant portion of this TAM, aiming for continued market leadership through innovation and strategic expansion.
Upturn SWOT Analysis
Strengths
- Diversified product and service portfolio across multiple scientific disciplines.
- Strong global brand recognition and established customer relationships.
- Extensive distribution network and sales force.
- Proven track record of successful mergers and acquisitions.
- Significant investment in research and development.
- Scale and financial resources to invest in growth opportunities.
Weaknesses
- Reliance on key product categories and market segments.
- Potential integration challenges from frequent acquisitions.
- Exposure to competitive pricing pressures in certain segments.
- Complex supply chain management across a global operation.
Opportunities
- Growing demand for biopharmaceutical manufacturing and R&D.
- Expansion in emerging markets.
- Advancements in genomics, proteomics, and personalized medicine.
- Increasing focus on diagnostic testing and healthcare analytics.
- Leveraging AI and digital technologies for enhanced customer solutions.
- Further strategic acquisitions to expand capabilities and market reach.
Threats
- Intense competition from established and emerging players.
- Economic downturns affecting research and development spending.
- Regulatory changes and compliance requirements.
- Supply chain disruptions and raw material price volatility.
- Intellectual property challenges and patent expirations.
- Geopolitical risks and trade policy changes.
Competitors and Market Share
Key Competitors
- Agilent Technologies (A)
- Danaher Corporation (DHR)
- Illumina, Inc. (ILMN)
- Merck KGaA (MRK.DE)
- Avantor, Inc. (AVTR)
Competitive Landscape
Thermo Fisher Scientific's main advantage lies in its comprehensive portfolio and its ability to offer end-to-end solutions, acting as a one-stop shop for many scientific needs. This breadth differentiates it from more specialized competitors. However, competitors like Agilent and Danaher are also strong players with deep expertise in specific areas, and Illumina dominates the NGS market. Thermo Fisher's challenge is to maintain innovation and operational excellence across its vast offerings while facing competition that can be highly focused and agile within their niche markets.
Major Acquisitions
PPD, Inc.
- Year: 2021
- Acquisition Price (USD millions): 17400
- Strategic Rationale: Acquisition of a leading global contract research organization (CRO) to significantly expand its presence in the clinical research services market and support biopharmaceutical customers across the drug development lifecycle.
Qiagen N.V. (Attempted, unsuccessful)
- Year: 2020
- Acquisition Price (USD millions): 11700
- Strategic Rationale: Attempted acquisition to broaden its diagnostics and molecular testing capabilities, particularly in response to the COVID-19 pandemic. The deal ultimately did not proceed due to regulatory concerns.
Unity Lab Services (Integrated)
- Year: 2017
- Acquisition Price (USD millions):
- Strategic Rationale: Expansion of its services business to provide comprehensive lab support, including equipment maintenance, calibration, and IT services, to enhance customer productivity and operational efficiency.
Growth Trajectory and Initiatives
Historical Growth: Thermo Fisher Scientific has a strong history of consistent and substantial growth, driven by organic expansion and a highly effective acquisition strategy. The company has consistently outperformed many of its peers by strategically expanding its offerings and market presence. Its growth has been fueled by its ability to adapt to evolving scientific needs and capitalize on emerging trends in life sciences and healthcare.
Future Projections: Analyst projections for Thermo Fisher Scientific generally indicate continued strong revenue and earnings growth. Key drivers are expected to include ongoing demand for biopharmaceutical tools, advancements in diagnostics, and contributions from its expanding portfolio of digital and integrated solutions. The company is well-positioned to benefit from long-term secular growth trends in its served markets.
Recent Initiatives: Recent strategic initiatives include significant investments in expanding manufacturing capacity for biologics, further integration of its analytical instrument offerings, and development of digital solutions to enhance customer workflows. The company has also continued its active acquisition strategy, targeting companies that complement its existing businesses and expand its technological capabilities.
Summary
Thermo Fisher Scientific Inc. is a dominant force in the scientific instrumentation and services market, demonstrating robust financial performance and consistent growth. Its broad portfolio, strategic acquisitions, and global reach are significant strengths. The company is well-positioned to capitalize on secular growth trends in life sciences and healthcare. Key areas to monitor include continued integration of acquisitions and navigating intense competition, but its diversified model provides resilience.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Thermo Fisher Scientific Inc. Investor Relations Filings (SEC)
- Annual Reports and Financial Statements
- Industry Analyst Reports
- Financial Data Aggregators (e.g., Refinitiv, Bloomberg)
- Market Research Publications
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Stock market data and company performance are subject to change and inherent risks. Users should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Market share data is based on estimates and can vary depending on the specific segment and methodology.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Thermo Fisher Scientific Inc
Exchange NYSE | Headquaters Waltham, MA, United States | ||
IPO Launch date 1978-01-13 | Chairman, President & CEO Mr. Marc N. Casper | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 125000 | Website https://www.thermofisher.com |
Full time employees 125000 | Website https://www.thermofisher.com | ||
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of drugs and vaccines, as well as diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment includes clinical diagnostics offering liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics offers develops, manufactures, and markets complete blood test systems to support the clinical diagnosis and monitoring of allergy, asthma, and autoimmune diseases; microbiology offers dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; transplant diagnostics products include human leukocyte antigen typing and testing for organ transplant market; and healthcare market channel offers consumables, diagnostic kits and reagents, equipment, instruments, solutions, and services. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.